Oramed Pharmaceuticals (ORMP) Accounts Payables (2011 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Accounts Payables came in at $8.5 million in Q1 2026, up 61.54% YoY from $5.3 million in Q1 2025, and up 1823.48% on a QoQ basis from $443000.0 in Q4 2025.
Oramed Pharmaceuticals (ORMP) Accounts Payables (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 16 years of Accounts Payables data on file, last reported at $8.5 million in Q1 2026.
- Quarterly Accounts Payables rose 61.54% year-over-year to $8.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.5 million (up 61.54% YoY) and the FY2025 annual result came in at $443000.0, down 91.38% from the prior year.
- Accounts Payables grew to $8.5 million in Q1 2026, from $443000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $8.5 million in Q1 2026 to a low of $443000.0 in Q4 2025.
- A 5-year average of $3.4 million and a median of $3.5 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2024 — Accounts Payables surged 832.85% — and 2025, when it sank 91.38%.
- Tracing ORMP's Accounts Payables over 5 years: stood at $4.2 million in 2022, then slumped by 86.75% to $551000.0 in 2023, then surged by 832.85% to $5.1 million in 2024, then slumped by 91.38% to $443000.0 in 2025, then soared by 1823.48% to $8.5 million in 2026.
- The last three Accounts Payables figures came in at $8.5 million (Q1 2026), $443000.0 (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - | 8.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.51 Mn |
| Mar 31, 2026 | 8.52 Mn |
| Dec 31, 2025 | 443,000.00 |
| Sep 30, 2025 | 4.86 Mn |
| Jun 30, 2025 | 715,000.00 |
| Mar 31, 2025 | 5.28 Mn |
| Dec 31, 2024 | 5.14 Mn |
| Sep 30, 2024 | 5.00 Mn |
| Jun 30, 2024 | 3.48 Mn |
| Mar 31, 2024 | 1.27 Mn |
| Dec 31, 2023 | 551,000.00 |
| Sep 30, 2023 | 2.56 Mn |
| Jun 30, 2023 | 828,000.00 |
| Mar 31, 2023 | 4.06 Mn |
| Dec 31, 2022 | 4.16 Mn |
| Sep 30, 2022 | 4.21 Mn |
| Jun 30, 2022 | 3.48 Mn |
| Mar 31, 2022 | 3.31 Mn |
| Nov 30, 2021 | 4.76 Mn |
| Aug 31, 2021 | 3.79 Mn |